Bicara Therapeutics 获得 TD Cowen 和 Stifel Nicolaus 的“买入”评级，目标价为 47 美元。 Bicara Therapeutics receives 'buy' ratings from TD Cowen and Stifel Nicolaus with a $47 price target.
Bicara治疗公司是一家临床阶段生物制药公司,重点是固态肿瘤的双功能疗法。 该公司获得了“买”评级,从TD Cowen和Stifel Nicolaus获得47美元的价格目标。 Bicara Therapeutics, a clinical-stage biopharmaceutical firm focused on bifunctional therapies for solid tumors, has received 'buy' ratings and a $47 price target from TD Cowen and Stifel Nicolaus. 股票以19.00美元开放。 The stock opened at $19.00. 主要股东,包括Ra Capital Management和James E.Flynn最近购买了大量股份。 Major shareholders, including Ra Capital Management and James E. Flynn, have recently purchased significant shares. 该公司的主导项目是 ficerafusp alfa，旨在治疗实体瘤。 The company's lead program is ficerafusp alfa, designed to treat solid tumors.